Oncology
5,176 studies502 in 7 days2,477 in 30 days
Filters
Latest
5,176 studies
- 118 LAT1 (SLC7A5) expression shapes the colorectal cancer tumor immunemicroenvironment and independently predicts time to next treatment
- 891 Pre-clinical development of a best-in-class bispecific T cell engager targeting a highly abundant peptide for the treatment of melanoma
- 431 The role of Ly6cHigh macrophages in mediating anti-CTLA4 response in immune-hot DNA mismatch repair-deficient tumors
- 811 AR166, a novel tri-specific immunocytokine, overcomes anti-PD-1 resistance by delivering cis-acting IL-2v via dual PD-1 and LAG-3 targeting
- 566 OBX-115 TIL cell therapy in ICI-resistant advanced melanoma: pooled safety and updated efficacy with minimally invasive tumor tissue procurement, low-dose lymphodepletion, and IL2-free regimen
- 1105 HER3 inhibition sensitizes metastatic colorectal and pancreatic cancer to immunotherapy
- 183 An accelerated, scalable manufacturing platform generates highly purified and functionally superior CAR T cell products for chronic lymphocytic leukemia
- 251 Product characterization of a clinical-grade BCMA CAR-MIL therapy supports IND-enabling development for multiple myeloma
- 318 CAR-T and CAR-NK cell combination therapy targeting DLL3 or CD70 surface antigens promotes synergistic antitumor activity in small cell lung cancer
- 89 Immunohistochemistry panel design with directly-conjugated antibodies for spatial characterization of the tumor immune microenvironment
- 1143 Obesity promotes interferon-driven regulatory T-cell activation and CD8 T-cell exhaustion in triple-negative breast cancer
- 197 Chimeric antigen receptor T-cell therapy in glioblastoma: a systematic review and meta analysis of early phase clinical trials with GRADE assessment
- 447 Molecular and immunological characterization of anti-PD-L1 response in GEMM-derived melanoma cell lines
- 1061 Anchored immunotherapy with CD137 (4-1BB) and CD122 (IL-2/15Rβ) multi-agonists induce monotherapy anti-tumor immunity and abscopal responses without systemic toxicity
- 993 Optimizing management of immune checkpoint inhibitor-mediated toxicity in cancer patients
- 200 Preclinical evaluation of a tandem PD-L1/EphA2 CAR-T cell therapy in multiple solid tumor models
- Muscle and tissue radiodensity matter: Automated CT-based body composition analysis predicts survival in hepatocellular carcinoma patients undergoing degradable starch microspheres transarterial chemoembolization (DSM-TACE)
- 611 Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in doublet checkpoint inhibitor-refractory melanoma: promising activity in an ongoing phase 1/2 study
- Regional Vulnerability to Brain Metastases Reflects Structural, Metabolic and Genetic Organization of the Healthy Brain
- Cyclin-Dependent Kinases 4/6 Inhibition in Glioblastoma: From Molecular Rationale to Therapeutic Challenges and Opportunities
- Efficacy and Safety of Monoclonal Antibodies in the Treatment of HER2-Positive Breast Cancer: A Systematic Review
- Measured Postoperative DL,CO and FEV1 Frequently Exceed Segment-Count Predictions After Lung Cancer Surgery: A Retrospective Cohort Study
- Selected Demographic and Temperamental Characteristics of Patients with Lung Cancer and Their Associations with Disease Acceptance, Negative Emotional Experiences, and Hope
- Perioperative and Long-Term Outcomes of Surgery in Patients Aged 80 Years or Older with Esophageal or Esophagogastric Junction Cancer: A Propensity Score–Matched Analysis
- Achievement and Persistence of MRD Negativity with Anti-CD38-Based Regimens in Newly Diagnosed Multiple Myeloma: A Systematic Review and Network Meta-Analysis